Finn RS - Search Results

1

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Llovet JM, et al. Among authors: finn rs. Nat Rev Clin Oncol. 2015 Jul;12(7):408-24. doi: 10.1038/nrclinonc.2015.103. Epub 2015 Jun 9. Nat Rev Clin Oncol. 2015. PMID: 26054909 Review.

2

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.

Finn RS, Zhu AX. Finn RS, et al. Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. doi: 10.1586/era.09.6. Expert Rev Anticancer Ther. 2009. PMID: 19374603 Review.

3

Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?

Finn RS. Finn RS. Clin Cancer Res. 2010 Jan 15;16(2):390-7. doi: 10.1158/1078-0432.CCR-09-2084. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068087 Review.

4

Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.

Saab S, McTigue M, Finn RS, Busuttil RW. Saab S, et al. Among authors: finn rs. Exp Clin Transplant. 2010 Dec;8(4):307-13. Exp Clin Transplant. 2010. PMID: 21143097 Free article.

5

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.

Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Clavien PA, et al. Lancet Oncol. 2012 Jan;13(1):e11-22. doi: 10.1016/S1470-2045(11)70175-9. Epub 2011 Oct 31. Lancet Oncol. 2012. PMID: 22047762 Free PMC article.

6

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW. Finn RS, et al. Clin Cancer Res. 2012 Apr 1;18(7):2090-8. doi: 10.1158/1078-0432.CCR-11-1991. Epub 2012 Jan 11. Clin Cancer Res. 2012. PMID: 22238246 Clinical Trial.

7

Advanced HCC: emerging molecular therapies.

Finn RS. Finn RS. Minerva Gastroenterol Dietol. 2012 Mar;58(1):25-34. Minerva Gastroenterol Dietol. 2012. PMID: 22419002 Review.

8

Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.

Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. Finn RS, et al. Hepatology. 2013 May;57(5):1838-46. doi: 10.1002/hep.26223. Epub 2013 Apr 1. Hepatology. 2013. PMID: 23299860

9

Emerging targeted strategies in advanced hepatocellular carcinoma.

Finn RS. Finn RS. Semin Liver Dis. 2013 Feb;33 Suppl 1:S11-9. doi: 10.1055/s-0033-1333632. Epub 2013 Mar 1. Semin Liver Dis. 2013. PMID: 23457035 Free article. Review.

10

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Finn RS, et al. J Hepatol. 2013 Dec;59(6):1271-7. doi: 10.1016/j.jhep.2013.07.029. Epub 2013 Aug 6. J Hepatol. 2013. PMID: 23928403 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters